Financial Data and Key Metrics Changes - The company reported fourth quarter revenue of $660.5 million, a decrease of 5.2% year-over-year, primarily due to lower pass-through costs in clinical pharmacology and clinical development businesses [24] - Full year 2025 revenue was $2,723.4 million, reflecting a 1% increase year-over-year, driven mainly by higher revenue in the clinical pharmacology business [25] - Adjusted EBITDA for the fourth quarter was $54 million, down from $56 million in the prior year, while full year adjusted EBITDA was $189.9 million, towards the higher end of guidance [27][28] - The company achieved gross savings of approximately $153 million and net savings of $93 million for the year, exceeding original targets [24] Business Line Data and Key Metrics Changes - The clinical pharmacology business saw increased revenue, contributing to the overall revenue growth, while FSP revenue continued to face headwinds [25] - The company secured significant new and repeat wins in Q4, including a long-term clinical pharmacology partnership with a top five large pharma company [11] Market Data and Key Metrics Changes - The macro environment showed signs of stabilization and early recovery, with funding activity rebounding significantly in the second half of 2025 [9] - Client engagement levels increased, with shorter decision-making timelines and more constructive conversations, particularly in the biotech sector [9][43] Company Strategy and Development Direction - The company is focused on disciplined execution and positioning itself to benefit from improving market conditions, emphasizing commercial, operational, and financial excellence [10][22] - The strategy includes expanding client relationships, enhancing operational efficiencies, and leveraging technology, particularly AI, to improve service delivery [16][17] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism about the recovery in the first half of 2026, citing improved client engagement and decision-making timelines [10][42] - The company anticipates a gradual improvement in margins as revenue grows, supported by ongoing cost optimization initiatives [36][46] Other Important Information - The company paid down approximately $76 million of senior secured notes in Q4, reinforcing its commitment to financial discipline [24] - The backlog stood at $7.7 billion, with a book-to-bill ratio of 1.14x for the quarter and 1.02x for the trailing twelve months [27] Q&A Session Summary Question: Outlook on the overall backdrop, particularly on biotech - Management noted signs of improvement and stabilization in the market, with increased client engagement and shorter decision-making timelines [42] Question: Key margin levers and revenue growth impact - Management indicated that revenue growth is crucial for margin improvement, with expectations of strong flow-through when demand returns [46] Question: Insights on bookings mix and RFP flow - Management reported a healthy mix of phase II and phase III studies, with increased RFP flow from biotech clients [61] Question: AI's impact on customer conversations and differentiation - Management emphasized that AI is viewed as a force multiplier, enhancing execution rather than replacing human roles, and is becoming a key factor in customer decision-making [104]
Fortrea (FTRE) - 2025 Q4 - Earnings Call Transcript